A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML

Trial Profile

A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2018

At a glance

  • Drugs CDX 1401 (Primary) ; Decitabine (Primary) ; Nivolumab (Primary) ; Poly ICLC (Primary)
  • Indications Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Dec 2017 Planned initiation date changed from 15 Dec 2017 to 31 Jan 2018.
    • 06 Dec 2017 New trial record
    • 04 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 15 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top